Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human antibodies against hepatitis c virus (HCV) and uses thereof

a technology of human antibodies and hepatitis c virus, which is applied in the field of human antibodies against hepatitis c virus (hcv) and its use, can solve the problems of slow development of hcv vaccines, ineffective vaccines against emerging strains, and inability to alleviate the problems faced by millions of chronic hcv carriers worldwide, and achieves low immunogenicity, localization to appropriate sites, and high purification

Inactive Publication Date: 2014-05-15
UNIV OF MASSACHUSETTS
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention relates to human monoclonal antibodies that can be efficiently made and used to diagnose, prognose, and treat individuals exposed to HCV. These antibodies can be produced using various techniques and can be administered alone or in combination with other antibodies or vaccines to increase survival rates of subjects infected with HCV. The use of human monoclonal antibodies offers several advantages such as less immunogenicity, rapid treatment, and specificity to HCV. These antibodies can be highly purified and are recombinant, avoiding the potential of contamination with adventitious agents.

Problems solved by technology

The development of vaccines against HCV has been slowed by the extreme antigenic variability of the virus.
Even when available, vaccines will not alleviate the problems faced by millions of chronic HCV carriers worldwide.
However, these tend to be strain-specific and are ineffective against emerging strains.
Presently, the only therapy with any demonstrated efficacy against HCV-induced liver disease involves the use of alpha-MN, but this approach has achieved only limited success.
There is also evidence that alpha-IFN treatment is much less effective against some HCV genotypes than others.
Currently, no conventional drugs against HCV infection (other than alpha-IFN) have yet been developed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human antibodies against hepatitis c virus (HCV) and uses thereof
  • Human antibodies against hepatitis c virus (HCV) and uses thereof
  • Human antibodies against hepatitis c virus (HCV) and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of Anti-HCV Monoclonal Antibodies

[0274]Mouse Immunizations, Hybridoma Production and Selection

[0275]Transgenic mice comprising human immunoglobulin genes generated as described above in the section entitled “Generation of Human Monoclonal Antibodies in HuMab Mice” and supplied by Medarex, Milpitas, Calif., were immunized with a soluble version of the HCV genotype 1a E2 envelope glycoprotein. The antigen was administered in combination with Freund's complete or RMI adjuvant. Mouse sera responses were monitored by enzyme linked immunosorbent assay (ELISA) to soluble E2 protein (1a E2-661). Splenic B cells were isolated from the immunized animal and fused to mouse myeloma (P3X-AG8.653) cells using standard spleen cells fusion methods. Clonal hybridomas were generated and screened using ELISA for production of antibody reactive to E2-661. Positive hybridomas were tested for equivalent reactivity to HCV genotype 1a and genotype 1b E2-661 by ELISA with decreasing amounts of hyb...

example 2

Antibody Characterization

[0281]HCV Genotype 1a and 1b—Soluble E2 ELISA

[0282]The reactivity of human antibody 95-2 (FIG. 1A) and human antibody 83-128 (FIG. 1B) to soluble HCV genotype 1a E2-660 (triangles) and soluble HCV genotype 1b E2-661 (squares) was compared. ELISA plates were coated with 2 μg / ml of antigen and probed with antibody in two-fold dilutions. Bound antibody was detected with goat-anti-human secondary antibody conjugated to alkaline phosphatase and PNPP substrate. Both human antibodies, 95-2 and 83-128 were found to react equivalently to both genotypes (see FIG. 1). These experiments were also performed with the 95-14, 95-38 and 073-1 antibodies and all three recognized genotype 1a and 1b equivalently (data not shown).

[0283]Neutralization of HCV Pseudovirus from Multiple Genotypes

[0284]The capacity of human antibodies 95-2 and 83-128 to neutralize both multiple genotypes of HCV pseudovirus was determined using Hep3B cells. Five-fold dilutions of antibody were incubat...

example 3

Epitope Determination

[0289]Determination of which Region of the E2 Protein Human Antibodies 83-128 and 95-2 Recognize

[0290]To determine which region of the E2 protein human antibodies 83-128 and 95-2 recognize, carboxy-terminal truncations of mammalian expressed E2 protein were captured by lectin ELISA and probed with 83-128 and 95-2 (see FIG. 5 for map of constructs and FIG. 6 for ELISA data). Based on the data, the epitope for these antibodies is within amino acids 412-464 of E2. As expected, all antibodies (95-14, 95-49, 95-62, 95-42, 95-58, 95-25, 95-43, 95-54, 95-2, 95-38, and 073-1) also mapped to this region of the E2 protein.

[0291]To further define the epitope, bacterially expressed fusion protein was used because the smaller pieces of E2 did not express well in the mammalian system. The purified proteins were coated on an ELISA plate and probed with human antibodies 83-128 and 95-2 (see FIG. 7 for map of constructs and FIG. 8 for ELISA data). Both human antibodies 83-128 an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Isolated human monoclonal antibodies which bind to hepatitis C virus (HCV), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Description

RELATED APPLICATIONS[0001]This application claims priority to and the benefit of U.S. Provisional Patent Application No. 60 / 902,432, filed Feb. 21, 2007, for all subject matter common to said application. The disclosure of the above-mentioned application is hereby incorporated by reference herein in its entirety.BACKGROUND OF THE INVENTION[0002]Hepatitis C virus (HCV), originally named “non-A non-B hepatitis” (NANBH), is a positive, single-stranded RNA virus of the Flaviviridae family. Its genome contains a single long open reading frame which encodes a polyprotein of about three-thousand amino acid residues. (Choo et al. (1989) Science 244:359-362). The polyprotein is processed by the host cell and viral proteases into three major structural proteins and several non-structural proteins necessary for viral replication. The nucleotide sequence of HCV is highly variable, the most divergent isolates sharing only 60% nucleotide sequence homology. Several different genotypes of HCV with ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/10
CPCC07K16/109A61K39/00A61K39/29A61K2039/505A61K2039/5258C07K14/005C07K2317/21C07K2317/34C12N2770/24222C12N2770/24234A61K2039/55566A61K39/12A61P31/00A61P31/12A61P31/14C07K16/10A61K39/395
Inventor AMBROSINO, DONNA M.THOMAS, JR., WILLIAM D.BABCOCK, GREGORY J.BROERING, TERESASLOAN, SUSAN
Owner UNIV OF MASSACHUSETTS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com